Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression.

Rui-Lian Chen,Jun Zhao,Xu-Chao Zhang,Na-Na Lou,Hua-Jun Chen,Xue Yang,Jian Su,Zhi Xie,Qing Zhou,Hai-Yan Tu,Wen-Zhao Zhong,Hong-Hong Yan,Wei-Bang Guo,Yi-Long Wu,Jin-Ji Yang

BMC cancer（2018）

引用 22|浏览28

暂无评分

摘要

C-Met overexpression co-exists with ALK rearrangement in a small population of advanced NSCLC. There may be a trend of favorable efficacy of crizotinib in such co-altered patients.

查看译文

关键词

Anaplastic lymphoma kinase,Mesenchymal epithelial transition,Non-small-cell lung cancer,Rearrangement,C-Met,overexpression

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要